These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23738533)

  • 1. Targeting liver X receptors in inflammation.
    Steffensen KR; Jakobsson T; Gustafsson JÅ
    Expert Opin Ther Targets; 2013 Aug; 17(8):977-90. PubMed ID: 23738533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities.
    Jakobsson T; Treuter E; Gustafsson JÅ; Steffensen KR
    Trends Pharmacol Sci; 2012 Jul; 33(7):394-404. PubMed ID: 22541735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver X receptors as potential therapeutic targets in atherosclerosis.
    Zhu Y; Li Y
    Clin Invest Med; 2009 Oct; 32(5):E383-94. PubMed ID: 19796580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver X receptors: From pharmacology to nanoparticle-based drug delivery.
    Hua X; Wei X
    Eur J Pharmacol; 2023 Oct; 956():175953. PubMed ID: 37541371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver X receptor: from metabolism to cancer.
    Venteclef N; Ferré P
    Biochem J; 2014 Apr; 459(2):e1-3. PubMed ID: 24678940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal negative cross-talk between liver X receptors (LXRs) and STAT1: effects on IFN-γ-induced inflammatory responses and LXR-dependent gene expression.
    Pascual-García M; Rué L; León T; Julve J; Carbó JM; Matalonga J; Auer H; Celada A; Escolà-Gil JC; Steffensen KR; Pérez-Navarro E; Valledor AF
    J Immunol; 2013 Jun; 190(12):6520-32. PubMed ID: 23686490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver X receptor: a potential target in the treatment of atherosclerosis.
    Savla SR; Prabhavalkar KS; Bhatt LK
    Expert Opin Ther Targets; 2022 Jul; 26(7):645-658. PubMed ID: 36003057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biology and functional genomics of liver X receptors (LXR) in relationship to metabolic diseases.
    Faulds MH; Zhao C; Dahlman-Wright K
    Curr Opin Pharmacol; 2010 Dec; 10(6):692-7. PubMed ID: 20829110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging roles of liver X receptors and their ligands in cancer.
    Lin CY; Vedin LL; Steffensen KR
    Expert Opin Ther Targets; 2016; 20(1):61-71. PubMed ID: 26788589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver X receptors, atherosclerosis and inflammation.
    Michael DR; Ashlin TG; Buckley ML; Ramji DP
    Curr Atheroscler Rep; 2012 Jun; 14(3):284-93. PubMed ID: 22419222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxysterol receptors and their therapeutic applications in cancer conditions.
    De Boussac H; Alioui A; Viennois E; Dufour J; Trousson A; Vega A; Guy L; Volle DH; Lobaccaro JM; Baron S
    Expert Opin Ther Targets; 2013 Sep; 17(9):1029-38. PubMed ID: 23875732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological roles of liver X receptors in immune cells.
    Pascual-García M; Valledor AF
    Arch Immunol Ther Exp (Warsz); 2012 Aug; 60(4):235-49. PubMed ID: 22696047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver x receptors in atherosclerosis and inflammation.
    Im SS; Osborne TF
    Circ Res; 2011 Apr; 108(8):996-1001. PubMed ID: 21493922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oxysterol receptors LXRα and LXRβ suppress proliferation in the colon.
    Vedin LL; Gustafsson JÅ; Steffensen KR
    Mol Carcinog; 2013 Nov; 52(11):835-44. PubMed ID: 22610535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver X receptor modulators: a review of recently patented compounds (2009 - 2012).
    Loren J; Huang Z; Laffitte BA; Molteni V
    Expert Opin Ther Pat; 2013 Oct; 23(10):1317-35. PubMed ID: 23826715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design.
    Oosterveer MH; Grefhorst A; Groen AK; Kuipers F
    Prog Lipid Res; 2010 Oct; 49(4):343-52. PubMed ID: 20363253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver x receptor signaling pathways and atherosclerosis.
    Calkin AC; Tontonoz P
    Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1513-8. PubMed ID: 20631351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic opportunities for liver X receptor modulators.
    Collins JL
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):692-702. PubMed ID: 15503871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LXR{beta} is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux.
    Hessvik NP; Boekschoten MV; Baltzersen MA; Kersten S; Xu X; Andersén H; Rustan AC; Thoresen GH
    Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E602-13. PubMed ID: 19996385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver X receptors as integrators of metabolic and inflammatory signaling.
    Zelcer N; Tontonoz P
    J Clin Invest; 2006 Mar; 116(3):607-14. PubMed ID: 16511593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.